Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Aug 25 (Reuters) - Recent clinical trial results are likely

to lead doctors to treat more patients who have a common form of

lung cancer with a Merck drug at the expense of a

Bristol-Myers Squibb medication at least until more data

emerges, oncologists and analysts say.

Read more